PRoFESS(R) Results Announced At XVII European Stroke Conference

In further exploratory analysis of the major lower endpoint of the composite of pat, myocardial infarction or vascular demise, AGGRENOX and clopidogrel lay naked equivalent outcome (13.1% versus 13.1%).(1) In PRoFESS, the AGGRENOX arm own a lofty digit of hemorrhagic stroke compare to clopidogrel (0.8% and 0.4%, respectively) while ischemic stroke recurrences be minor body repetitive contained close the AGGRENOX arm compared to the clopidogrel arm (7.7% and 7.9%, respectively).(1) A post-hoc analysis showed comparable numbers of death and disable strokes and a similar neurological end in situation of measured by the customized Rankin Scale(2) at three months after the returning stroke and at the close of the PRoFESS try-out relating the two remedy armaments.(1) Major hemorrhagic trial were observed more incessantly in the AGGRENOX horde compared with clopidogrel (4.1% versus 3.6%; HR 1.15, 95% CI 1.00-1.32). The benefit-risk ratio expressed as the fusion of recurrent stroke and unproved hemorrhage be not considerably conflicting between AGGRENOX and clopidogrel (11.7% and 11.4% respectively; HR 1.03, 95% CI 0.95-1.11).(1) "Given the high high proportion of stroke and recurrent stroke in aging society, physician plan a length of treatment option consequently they can volunteer patients a regimen tailored to their personal desires," said Professor Hans-Christoph Diener, MD, University of Essen, Germany, one of the three principal investigators of the search. "Landmark trial similar to PRoFESS will confer a mitt clinicians label evidence-based treatment stretch and ensure that patients receive optimal analysis in give your acclamation to of their emergency." The other regimen tested in PRoFESS seek whether Micardis(R) tablets, integrated with median antiplatelet therapy, can further soften the chance of recurrent stroke. At the end of the study, the grades demonstrated that 8.7% of patients weathered recurrent stroke in the MICARDIS arm versus 9.2% in the placebo arm (p=0.23). Thus, the primary endpoint of prominence of MICARDIS versus placebo could not be statistically confirmed. The show follow-on occupancy was 2.5 years, and it be misty whether a longer follow-up period would have let go statistical weightiness. The PRoFESS results snatch near to on to support the safekeeping and tolerability profile of MICARDIS.

Medicines from an impotence articles tabletsguide now

Read more about privacy policy